e-learning
resources
Stockholm 2002
Monday 16.09.2002
Miscellaneous respiratory infections in children
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of immunotherapy with ribomunyl in children with recurrent respiratory infections: results of 3-year prospective study
N. A. Korovina, A. L. Zaplatnikov, A. V. Suzdalenkov (Moscow, Russia)
Source:
Annual Congress 2002 - Miscellaneous respiratory infections in children
Session:
Miscellaneous respiratory infections in children
Session type:
Thematic Poster Session
Number:
2101
Disease area:
Paediatric lung diseases
Abstract
We analyzed the health status of 238 children aged 1-6 years who attended kindergarten or nursery. Frequent recurrent respiratory infections were found in 53 children (22%). Thirty-five children aged 3-6 year with frequent recurrent respiratory infections were enrolled into open comparative randomized trial to study efficacy of 3 months treatment with Ribomunyl. The follow-up period was 3 years. In first 18 months of follow-up the frequency of respiratory infections in treatment group decreased in 1.74 times vs baseline (p<0.05) and in 1.5 times vs control group (p<0.05). Further, Ribomunyl provided decrease of antibacterial agents usage in 1.82 times vs baseline (p<0.05) and in 1.76 times vs control group (p<0.05). The epidemiological efficacy coefficient at peak of respiratory infections season was 43.3% on the first year of follow-up, the epidemiological efficacy index was 1.8 (p<0.05). Tolerability of Ribomunyl was excellent.
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. A. Korovina, A. L. Zaplatnikov, A. V. Suzdalenkov (Moscow, Russia). Efficacy of immunotherapy with ribomunyl in children with recurrent respiratory infections: results of 3-year prospective study. Eur Respir J 2002; 20: Suppl. 38, 2101
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study
Source: Eur Respir J, 50 (5) 1700434; 10.1183/13993003.00434-2017
Year: 2017
Bacterial infections during acute exacerbations of COPD; a one-year prospective study
Source: Eur Respir J 2001; 18: Suppl. 33, 183s
Year: 2001
The results of a randomized clinical trial of the efficacy of the antibodies-based drug in influenza and acute respiratory viral infections in children
Source: International Congress 2019 – New insights into childhood infections: from viral bronchiolitis to bronchiolitis obliterans
Year: 2019
Tofacitinib versus standard of care treatment in patients with COVID-19 pneumonia and respiratory failure: a multicenter cohort study
Source: Virtual Congress 2021 – Acute COVID - 19
Year: 2021
Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study
Source: Eur Respir J, 55 (5) 2000524; 10.1183/13993003.00524-2020
Year: 2020
Efficacy of isoniazid preventive therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders-a retrospective cohort study in Taiwan
Source: International Congress 2017 – Migrants and screening
Year: 2017
Efficacy and safety of sequential three-step empirical therapy for chronic cough: a multi-center clinical study
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Acute lower respiratory tract infections in children: a prospective etiologyc study
Source: Annual Congress 2008 - Miscellaneous respiratory infections
Year: 2008
Epidemiological multicentre study on the incidence of RSV respiratory infections in early childhood in Italy
Source: Eur Respir J 2002; 20: Suppl. 38, 17s
Year: 2002
Pneumococcal vaccination in chronic respiratory patients – a cohort study
Source: International Congress 2019 – Airway infection in COPD
Year: 2019
Observational study of respiratory tract microflora in CF patients over a 15-year period
Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring
Year: 2017
COVID-19 pneumonia and clinical follow-up: results of a prospective cohort
Source: Virtual Congress 2021 – COVID - 19 risk predictions
Year: 2021
Predictors for detecting chronic respiratory diseases in population surveys: a pilot study for RESPIRE 4CCORD study
Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases
Year: 2021
Efficacy of antifibrotics in chronic hypersensitivity pneumonitis. A 3 year real-life observational study
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020
Comparative prospective cohort study of the efficacy and safety according to dose of Ceftriaxone in community-acquired pneumonia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
Palivizumab prophylaxis, respiratory syncytial virus and subsequent recurrent wheezing: a 2-year follow-up study
Source: Eur Respir J 2006; 28: Suppl. 50, 758s
Year: 2006
Impact of steroid therapy on exacerbation of chronic obstructive pulmonary disease with community-onset pneumonia: a multicenter retrospective cohort study
Source: Virtual Congress 2020 – Prognosis and integrated management of COPD
Year: 2020
Efficacy of roflumilast in patients with a history of frequent exacerbations: Pooled data from pivotal 12-month studies
Source: Annual Congress 2010 - COPD: management
Year: 2010
Intermittent tiotropium in early childhood wheezing? Preliminary safety results of a pilot study
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
Immunotherapy as a preventive treatment for new onset asthma? A hospital-based retrospective cohort study
Source: Eur Respir J 2005; 26: Suppl. 49, 134s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept